Low dose DNA methyltransferase inhibitors potentiate PARP inhibitors in homologous recombination repair deficient tumors
We conclude that low dose DNA methyltransferase inhibition can cooperate with low dose PARP inhibition to increase DNA damage predominantly in cells with HRR deficiencies, ultimately producing more cell death than in HRR proficient tumors. We predict that clinical benefit will more likely be apparent in patients with DNA repair defective tumors and are focusing clinical exploration of this drug combination in these patients, with the goals of enhancing tumor cell death at minimal toxicities.
Authors
- Ann Lazar (ORCID: https://orcid.org/0000-0002-6341-0360)
- Romain Pacaud (ORCID: https://orcid.org/0000-0002-4352-0976)
- Pamela N. Münster (ORCID: https://orcid.org/0000-0002-2074-0984)
- Sibapriya Chaudhuri
- Scott Thomas
- Luika Timmerman
Institutions
- University of California, San Francisco (US)
- UCSF Helen Diller Family Comprehensive Cancer Center (US)
Publication Details
- Journal
- Breast Cancer Research
- Published
- 2025-01-16
- DOI
- https://doi.org/10.1186/s13058-024-01954-y
- Citations
- 10
- Primary Topic
- PARP inhibition in cancer therapy
- Type
- article
- Field-Weighted Citation Impact
- 10.45
Funders
- National Institutes of Health
- University of California, San Francisco
- Helen Diller Family Comprehensive Cancer Center, University of California, San Francisco